ScripIn the space of only a few years, immunoglobulin A nephropathy (IgAN) has gone from no drug therapies available to three options on a list that is growing. The questions that remain now are how to seg
Pink SheetUS Food and Drug Administration approval decisions for endocrine and metabolic disease therapies will crescendo through the rest of 2024, and could briefly make more noise than the perpetually dominan
ScripPresident-elect Donald Trump’s plan to nominate Robert F. Kennedy Jr. as secretary of the US Department of Health and Human Services was not entirely unexpected, but it sent biopharmaceutical stock va
ScripWith now three drugs for immunoglobulin A nephropathy (IgAN) having US Food and Drug Administration approval, the disease has become a competitive space, one into which Otsuka Pharmaceutical Co. Ltd.